πΉ “Zuclopenthixol Decanoate API – Properties, Uses, and Manufacturing Insights by Swapnroop Drugs & Pharmaceuticals”
π Q1 — What is Zuclopenthixol Decanoate manufactured by Swapnroop Drugs & Pharmaceuticals?
Zuclopenthixol decanoate is a long-acting injectable antipsychotic (depot) API from the thioxanthene class of typical antipsychotics. Swapnroop Drugs & Pharmaceuticals produces it as a pharmaceutical-grade API, intended primarily for formulation into intramuscular depot injections used for maintenance therapy in chronic psychotic disorders, such as schizophrenia. π§ͺπ₯
π§ Pharmacology & Mechanism
-
Class: Typical antipsychotic (thioxanthene derivative)
-
Mechanism: Acts as a dopamine D₂ receptor antagonist, reducing dopaminergic overactivity that contributes to psychotic symptoms like hallucinations and delusions.
-
Additional Effects: Partial antagonism at Ξ±-adrenergic and histamine H₁ receptors contributes to sedation and mild hypotension. ⚖️π§¬
π©Ί Clinical Role & Typical Use Cases
-
Primary Use: Long-term maintenance therapy in schizophrenia or other chronic psychotic disorders. π₯
-
Administration: Given as intramuscular depot injections every 2–4 weeks to ensure sustained plasma levels. ⏱️π
-
Benefits: Improves treatment adherence, reduces relapse rates, and minimizes frequent oral dosing. π
π§Ύ Quality & Regulatory Profile (Swapnroop)
Swapnroop ensures the API is GMP-compliant and suitable for pharmaceutical manufacturing. Key features:
-
High Purity: ≥99% assay, with low impurities. π
-
Pharmacopeial Compliance: Meets IP/BP/EP/USP standards. ✔️
-
QC Documentation: Each batch includes Certificate of Analysis (CoA), impurity profile, and stability guidance. π
-
Intended Supply: For licensed pharmaceutical manufacturers who formulate sterile depot injections. π
π¬ Typical Physicochemical Properties
-
Appearance: White to off-white crystalline powder ❄️
-
Solubility: Insoluble in water; soluble in organic solvents (e.g., ethanol, chloroform). π§
-
Molecular Weight: 502.1 g/mol (C₂₉H₃₇ClN₂OS·C₇H₁₄O₂) ⚛️
-
Stability: Sensitive to light and moisture — requires controlled storage. π‘️
-
Depot Suitability: The decanoate ester allows slow hydrolysis, providing sustained release over weeks. ⏳
π Manufacturing & Supply Intent
-
Swapnroop supplies API, not finished product.
-
Formulation partners convert it into sterile IM depot injections, which release the drug gradually over weeks. π
-
Technical support: Swapnroop provides pre-formulation data, solubility info, and regulatory documentation to ensure compliance. π§Ύ
⚠️ Handling, Safety & Packaging
-
Handling: PPE required; controlled environment during weighing and dispensing. π§€π·
-
Packaging: Typically supplied in HDPE drums with inner liners or other pharma-grade containers. π¦
-
Storage: Protected from light, moisture, and extreme temperatures. π‘️π‘️
π§© Q2. What is Zuclopenthixol Decanoate by Swapnroop Drugs & Pharmaceuticals used for?
Zuclopenthixol Decanoate is a long-acting injectable antipsychotic used primarily for maintenance therapy in chronic psychotic disorders like schizophrenia. π§ π
πΉ Therapeutic Applications
-
Maintenance therapy: Prevents relapse in chronic psychosis. π₯
-
Ensures compliance: Reduces missed doses compared to oral antipsychotics. π
-
Stabilization: Provides steady plasma drug levels over 2–4 weeks per injection. ⏱️
-
Adjunct in acute management: Can be started after initial short-acting therapy (like Zuclopenthixol acetate) to maintain calm behavior. ⚡
π Clinical Benefits
-
Reduces relapse rates
-
Improves patient adherence and overall treatment outcomes
-
Minimizes oral dosing errors and frequent clinic visits
⚗️ Q3. What are the physicochemical properties of Zuclopenthixol Decanoate manufactured by Swapnroop Drugs & Pharmaceuticals?
π¬ Physicochemical Characteristics
| Property | Description |
|---|---|
| Chemical Name | Cis-(Z)-4-[3-(2-chloro-9H-thioxanthen-9-ylidene)propyl]-N,N-dimethylpiperazine-1-ethanamine decanoate |
| Molecular Formula | C₂₉H₃₇ClN₂OS·C₁₀H₂₀O₂ |
| Molecular Weight | ≈ 502.1 g/mol ⚛️ |
| Appearance | White to off-white crystalline powder ❄️ |
| Solubility | Practically insoluble in water π§; soluble in organic solvents like ethanol or chloroform |
| Melting Point | 75–80 °C π‘️ |
| Log P | ~6.0 → highly lipophilic π§ͺ |
| Stability | Sensitive to light and moisture; requires airtight, dry storage π‘️☀️ |
π‘ Key Note: The decanoate ester ensures slow hydrolysis, giving the drug its long-acting depot property.
⚙️ Q4. How is Zuclopenthixol Decanoate manufactured by Swapnroop Drugs & Pharmaceuticals?
𧬠Simplified Synthesis Pathway
-
Starting Material: Zuclopenthixol base (from thioxanthene derivative).
-
Esterification: Reaction with decanoic acid or its activated derivative → forms Zuclopenthixol decanoate. π§ͺ
-
Purification: Multiple recrystallizations to remove unreacted decanoate and impurities.
-
Drying & Milling: Dried under controlled conditions; milled for uniform particle size for depot suspension formulation. ⚖️
π§Ύ Quality & Control Checks
-
Assay and purity (HPLC ≥99%)
-
Residual solvents analysis (GC)
-
Moisture content and heavy metal testing
-
Particle size analysis for depot stability ⚙️
✅ Outcome: High-quality GMP-compliant API ready for sterile depot formulation.
π Q5. What are the different dosage forms of Zuclopenthixol Decanoate manufactured by Swapnroop Drugs & Pharmaceuticals?
π§΄ Common Market Dosage Forms
-
Long-acting IM Depot Injection:
-
Oil-based suspension (e.g., sesame oil)
-
Concentration: 50 mg/mL or 200 mg/mL π
-
-
Combination Kits:
-
Sometimes combined with short-acting Zuclopenthixol acetate for initial stabilization. π
-
π¦ Formulation Intent
-
Depot form provides sustained release over 2–4 weeks, reducing frequency of administration.
-
Ensures steady plasma levels → better symptom control and reduced relapse.
⚗️ Q6. How are Zuclopenthixol Decanoate dosage forms prepared?
π Typical IM Depot Suspension Manufacturing Steps
-
API Dispersion: Zuclopenthixol decanoate is dispersed in sterile oil vehicle (sesame oil or fractionated coconut oil). πΏ
-
Wetting & Stabilization: Surfactants added for uniform particle distribution.
-
Homogenization: Ensures smooth, uniform suspension ⚙️
-
Sterile Filtration or Aseptic Filling: Ensures sterility and absence of particulate contamination π¬
-
Filling & Sealing: Into amber vials or ampoules, maintaining sterility. π‘
-
Quality Testing: Assay, particle size, sterility, endotoxin, and uniformity checks. π§«
π‘ Note: Swapnroop supplies the API and technical guidance, while sterile depot formulation is done by licensed GMP facilities.
π Q7. What is the appropriate dosage form of Zuclopenthixol Decanoate manufactured by Swapnroop Drugs & Pharmaceuticals?
The appropriate dosage form is the long-acting intramuscular (IM) depot injection. π
⚙️ Why IM Depot Form?
-
Sustained release: Slowly hydrolyzed in muscle tissue, providing steady plasma levels for 2–4 weeks ⏳
-
Patient compliance: Eliminates need for daily oral dosing π
-
Safety: Reduces risk of missed doses and relapse in chronic psychosis π§
-
Strengths: Typically 50 mg/mL, 100 mg/mL, or 200 mg/mL depending on clinical need
✅ Summary: IM depot injection is the clinically and pharmaceutically appropriate form for long-term management.
π Q8. When should Zuclopenthixol Decanoate API be taken?
Zuclopenthixol Decanoate is not orally administered; it is formulated into IM depot injections given under medical supervision. π₯π
⏱️ Timing & Administration
-
Given every 2–4 weeks, depending on patient condition and prior oral stabilization.
-
Initiation may follow short-acting Zuclopenthixol acetate for rapid control. ⚡
-
Ensures continuous therapeutic levels for maintenance therapy, preventing relapse.
⚠️ Note: Administration and dosing must be guided by a qualified psychiatrist or healthcare professional.
π₯ Q9. What are the effects and side effects of Zuclopenthixol Decanoate?
πΏ Therapeutic Effects
-
Long-term control of psychotic symptoms (delusions, hallucinations) π§
-
Reduces agitation and aggression in chronic patients ⚖️
-
Provides steady plasma drug levels → stable symptom management ⏳
-
Improves treatment adherence and quality of life π
⚠️ Side Effects
| Category | Common Effects |
|---|---|
| π§ Neurological | Extrapyramidal symptoms (rigidity, tremor), akathisia, sedation |
| π Cardiovascular | Hypotension, rare tachycardia or arrhythmia |
| π΄ Sedation | Mild to moderate, usually at initiation |
| π§♂️ General | Weight gain, dry mouth, constipation, blurred vision |
| π Injection site | Pain, swelling, or irritation (temporary) |
π‘ Precautions:
-
Monitor elderly patients and those with cardiovascular disease.
-
Avoid alcohol or CNS depressants during therapy.
π§ͺ Q10. How is Zuclopenthixol Decanoate manufactured by Swapnroop Drugs & Pharmaceuticals tested?
Swapnroop ensures each API batch undergoes comprehensive quality control according to GMP and pharmacopeial standards. π§¬✔️
π§« Testing Includes
-
Identification Tests: IR spectroscopy, UV fingerprint, chemical confirmation π§ͺ
-
Assay: HPLC analysis for content and purity (≥99%) π
-
Impurity Analysis: HPLC or GC to detect degradation products
-
Residual Solvent Testing: GC to ensure safe solvent levels
-
Moisture Content: Karl Fischer or oven method π§
-
Particle Size Analysis: Ensures suitability for depot formulation ⚙️
-
Heavy Metals & Elemental Impurities: ICP-OES or AAS to meet ICH Q3D
-
Stability Studies: Monitored under accelerated and long-term conditions π‘️
π Documentation
-
Certificate of Analysis (CoA) for each batch
-
Batch Manufacturing Record (BMR)
-
Regulatory-compliant data for global markets π
𧬠Q11. What tests are performed on Zuclopenthixol Decanoate?
Here’s a detailed list of routine QC tests:
| π§ͺ Test | π§Ύ Purpose |
|---|---|
| Description / Appearance | Visual check for consistency |
| Identification (IR, UV, TLC) | Confirms chemical identity |
| Assay (HPLC) | Determines API purity (≥99%) |
| Related Substances | Detects impurities or degradation products |
| Water Content | Moisture level for stability |
| Residual Solvents (GC) | Confirms safe solvent levels per ICH Q3C |
| Heavy Metals | Ensures low elemental contamination |
| Particle Size Analysis | Ensures uniformity for depot formulation |
| Melting Point / DSC | Confirms crystallinity and polymorphic stability |
| Microbial Limits (if sterile grade) | Ensures absence of microorganisms π§« |
✅ Outcome: A pharmacopeia-compliant API suitable for long-acting depot formulations with predictable pharmacokinetics.
⚗️ Q12. What are the challenges in manufacturing Zuclopenthixol Decanoate API?
Producing Zuclopenthixol Decanoate is complex due to its chemical structure and long-acting nature. ⚙️
⚠️ Key Challenges
-
Purity & Impurity Control:
-
Multiple synthetic steps increase risk of process-related impurities. π¬
-
-
Esterification Reaction Control:
-
Precise conditions are needed for decanoate ester formation; deviations can reduce yield. ⚗️
-
-
Moisture Sensitivity:
-
Highly hygroscopic; moisture can cause hydrolysis or degradation. π§
-
-
Crystallization & Polymorphism:
-
Controlling particle size and crystal form is crucial for depot suspension performance. π
-
-
Residual Solvents:
-
Proper removal of organic solvents is essential to meet ICH Q3C guidelines. π§―
-
-
Regulatory Compliance:
-
Documentation for DMF, CoA, stability data is required for global approvals. ππ
-
π Q13. What are the challenges in manufacturing Zuclopenthixol Decanoate dosage forms?
Formulating long-acting IM depot injections involves multiple technical challenges. π§΄⚙️
π§ͺ Major Formulation Challenges
-
Sterile Processing:
-
Must be done under aseptic conditions in cleanrooms (Class 100/Grade A). π§Ό
-
-
Particle Size Control:
-
Too large → injection pain; too small → rapid release. π
-
-
Suspension Stability:
-
Uniform dispersion in oil vehicle (sesame oil, coconut oil) is critical πΏ
-
-
Viscosity Optimization:
-
Too viscous → injection difficulty; too thin → poor depot effect ⚖️
-
-
Sterility Assurance:
-
Final product must pass sterility, endotoxin, and particulate tests π¬
-
-
Packaging Compatibility:
-
Vial and stopper must be compatible with oil-based suspension π¦
-
-
Regulatory Validation:
-
Requires process validation per GMP, ICH Q8–Q10 standards π
-
✅ Result: Safe, uniform, long-acting depot injections with predictable pharmacokinetics.
❄️ Q14. What are the storage conditions for Zuclopenthixol Decanoate API?
Proper storage ensures stability and potency. π‘️
π‘️ Recommended Storage Conditions
| Parameter | Requirement |
|---|---|
| Temperature | 20–25°C (room temperature) |
| Humidity | <40% RH π«️ |
| Light Protection | Store in dark or amber containers ☀️❌ |
| Container Type | Airtight HDPE drums with inner liners π¦ |
| Handling | Avoid prolonged air/moisture exposure π§€ |
| Transport | Maintain temperature-controlled, moisture-free conditions π |
⚠️ Note: Improper storage may lead to hydrolysis, color change, or potency loss.
π¦ Q15. What is the packaging for Zuclopenthixol Decanoate API?
π API Packaging
-
Primary: HDPE drums with double polyethylene liners
-
Closure: Airtight and tamper-evident π
-
Labeling: Includes product name, batch number, manufacture/expiry date, storage instructions π·️
-
Capacity: 1 kg, 5 kg, 10 kg, or 25 kg drums
π Export / Transport Packaging
-
Cartons with shock-resistant padding
-
Desiccant sachets to maintain low humidity πΏ
-
Compliant with UN packaging regulations
π Formulated Depot Packaging
-
Amber glass vials or ampoules
-
Cartons with batch number, strength, storage instructions
-
Protects from light, moisture, and contamination π
⏳ Q16. What is the shelf life of Zuclopenthixol Decanoate API?
𧬠Shelf Life of API
-
Standard: 36 months (3 years) from manufacture date π
-
Storage: 20–25°C, protected from light and moisture π‘️
-
Packaging Integrity: Must remain sealed in original HDPE drums
π¬ Stability Studies
-
Accelerated: 40°C ±2°C / 75% RH ±5% for 6 months
-
Long-term: 25°C ±2°C / 60% RH ±5% for 36 months
-
Monitored Parameters: Assay, impurities, moisture content, physical appearance
✅ Result: API maintains ≥99% purity, stable crystallinity, suitable for depot formulations.
⚠️ Note: Once opened or improperly stored, shelf life may decrease — follow Swapnroop’s handling guidelines.

Comments
Post a Comment